Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

Fig. 5

Expansion and persistence of BM38 CAR-Ts associated with clinical response. The peak expansion and AUC0-28 days of BM38 CAR-Ts were associated with a sCR (a) and clinical response (b), but not with infused dose (d). Patients who achieved a sCR and responded had higher peak expansion on day 14 (c). An unpaired t test was used. Kaplan–Meier survival curves of in vivo BM38 CAR-Ts, overall (e) and by responses (f). The log-rank test was used

Back to article page